Search is Powered by Google
Blood / Hematology News

Mathematical Modeling May Help Leukemia Therapy

rate icon Editor's Choice
Main Category: Blood / Hematology
Also Included In: Cancer / Oncology
Article Date: 27 Jun 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

A study published in the open-access journal PLoS Computational Biology demonstrates how sophisticated mathematical modeling has encouraged the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML).

Researchers Doron Levy (University of Maryland), Peter P. Lee (Stanford University), and Peter S. Kim (École Supérieure d'Électricité, Gif-sur-Yvette, France) collected data over four years from CML patients who were receiving therapy with the drug imatinib. They then developed a mathematical model that uses a patient's natural anti-leukemia response when treated with imatinib to improve leukemia treatment.

"By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient," remarked Professor Doron Levy. "Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans."

Levy indicates that it is both the drug and the body's natural immune response that are responsible for leukemia remission. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak. This typically happens well into the treatment."

When this weakening occurs, cancer cells can begin to develop resistance to the drug, and the therapy cab become ineffective. It is at this point that the immune system needs to be strengthened, and the authors suggest irradiated pre-therapy blood should be introduced into the patient. The researchers maintain that further studies are necessary and should lead to animal models and clinical trials.

Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
Kim PS, Lee PP, Levy D
PLoS Computational Biology (2008). 4(6):e1000095.
doi:10.1371/journal.pcbi.1000095
Click Here to View Article

About PLoS Computational Biology

PLoS Computational Biology (www.ploscompbiol.org) features works of exceptional significance that further our understanding of living systems at all scales through the application of computational methods. All works published in PLoS Computational Biology are open access. Everything is immediately available subject only to the condition that the original authorship and source are properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today




Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader


Understanding Type 2 Diabetes
Understanding Type 2 Diabetes

Susan was devastated when she was diagnosed with type 2 diabetes. But learning about what causes the disease and how to get it under control has helped her live a healthy life.

more videos are available in our health videos section.